{"id":"erlotinib-standard-dose","safety":{"commonSideEffects":[{"rate":"30-50%","effect":"Rash"},{"rate":"20-40%","effect":"Diarrhea"},{"rate":"20-40%","effect":"Fatigue"},{"rate":"10-30%","effect":"Nausea"},{"rate":"10-30%","effect":"Vomiting"},{"rate":"10-30%","effect":"Anorexia"},{"rate":"5-20%","effect":"Dyspnea"},{"rate":"5-20%","effect":"Cough"},{"rate":"1-10%","effect":"Pneumonitis"},{"rate":"1-10%","effect":"Interstitial lung disease"}]},"_chembl":{"chemblId":"CHEMBL1079742","moleculeType":"Small molecule","molecularWeight":"429.90"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"By inhibiting the EGFR tyrosine kinase, erlotinib prevents the activation of downstream signaling pathways that promote cell proliferation and survival. This leads to the inhibition of tumor growth and induction of apoptosis in cancer cells. Erlotinib is particularly effective in tumors with EGFR mutations or overexpression.","oneSentence":"Erlotinib is a tyrosine kinase inhibitor that targets the epidermal growth factor receptor (EGFR) tyrosine kinase.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:51:45.906Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Non-small cell lung cancer"},{"name":"Pancreatic cancer"}]},"trialDetails":[{"nctId":"NCT00602667","phase":"PHASE2","title":"Risk-Adapted Therapy for Young Children With Embryonal Brain Tumors, Choroid Plexus Carcinoma, High Grade Glioma or Ependymoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"St. Jude Children's Research Hospital","startDate":"2007-12-17","conditions":"Brain and Central Nervous System Tumors","enrollment":293},{"nctId":"NCT02296125","phase":"PHASE3","title":"AZD9291 Versus Gefitinib or Erlotinib in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2014-12-03","conditions":"Locally Advanced or Metastatic EGFR Sensitising Mutation Positive Non Small Cell Lung Cancer","enrollment":674},{"nctId":"NCT00600496","phase":"PHASE1","title":"A Phase I, Open-Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD6244 (ARRY-142886)","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2007-12-14","conditions":"Breast Cancer, Breast Neoplasms, Colon Cancer","enrollment":140},{"nctId":"NCT03653546","phase":"PHASE2, PHASE3","title":"First Line Treatment in EGFR Mutation Positive Advanced NSCLC Patients With Central Nervous System (CNS) Metastases","status":"COMPLETED","sponsor":"Alpha Biopharma (Jiangsu) Co., Ltd.","startDate":"2018-10-29","conditions":"Non-small Cell Lung Cancer, EGFR Gene Mutation, Brain Metastases","enrollment":492},{"nctId":"NCT00954226","phase":"PHASE1","title":"Phase Ib Study of Erlotinib Prior to Surgery in Patients With Head and Neck Cancer","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2009-08-05","conditions":"Recurrent Head and Neck Carcinoma, Recurrent Salivary Gland Carcinoma, Recurrent Skin Carcinoma","enrollment":48},{"nctId":"NCT00954525","phase":"PHASE1","title":"Intravenous Vitamin C in Combination With Standard Chemotherapy for Pancreatic Cancer","status":"COMPLETED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University","startDate":"2009-07","conditions":"Metastatic Pancreatic Cancer","enrollment":14},{"nctId":"NCT00448240","phase":"PHASE2, PHASE3","title":"Erlotinib (Tarceva) During First Line Standard Platinum Containing Chemo for Advanced Squamous Cell Head and Neck Cancer","status":"TERMINATED","sponsor":"Henry Ford Health System","startDate":"2007-02","conditions":"Head and Neck Cancer, Carcinoma, Squamous Cell","enrollment":6},{"nctId":"NCT02424617","phase":"PHASE1, PHASE2","title":"A Study of BGB324 (Bemcentinib) in Combination With Erlotinib in Patients With Non-Small Cell Lung Cancer","status":"COMPLETED","sponsor":"BerGenBio ASA","startDate":"2015-04-19","conditions":"Non-Small Cell Lung Cancer","enrollment":40},{"nctId":"NCT06516887","phase":"PHASE1, PHASE2","title":"Study of Bemcentinib Plus Pacritinib In Patients With Advanced Lung Adenocarcinoma","status":"RECRUITING","sponsor":"The University of Texas Health Science Center at San Antonio","startDate":"2024-12-27","conditions":"Advanced Lung Adenocarcinoma","enrollment":44},{"nctId":"NCT00881166","phase":"PHASE1","title":"Safety of MP470 in Combination With Standard-of-Care Chemotherapy Regimens to Treat Solid Tumors","status":"COMPLETED","sponsor":"Astex Pharmaceuticals, Inc.","startDate":"2007-11","conditions":"Malignant Disease","enrollment":101},{"nctId":"NCT02352948","phase":"PHASE3","title":"A Global Study to Assess the Effects of MEDI4736 (Durvalumab), Given as Monotherapy or in Combination With Tremelimumab Determined by PD-L1 Expression Versus Standard of Care in Patients With Locally Advanced or Metastatic Non Small Cell Lung Cancer","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2015-01-13","conditions":"Non - Small Cell Lung Cancer NSCLC","enrollment":597},{"nctId":"NCT01068587","phase":"PHASE1, PHASE2","title":"MET/VEGFR2 Inhibitor GSK1363089 and Erlotinib Hydrochloride or Erlotinib Hydrochloride Alone in Locally Advanced or Metastatic NSCLC That Has Not Responded to Previous Chemotherapy","status":"COMPLETED","sponsor":"NCIC Clinical Trials Group","startDate":"2010-01-21","conditions":"Lung Cancer","enrollment":31},{"nctId":"NCT01257594","phase":"PHASE1","title":"EGFR Inhibition Using Weekly Erlotinib for Recurrent Malignant Gliomas","status":"COMPLETED","sponsor":"Andrew B Lassman, MD","startDate":"2011-01-07","conditions":"Brain Cancer","enrollment":22},{"nctId":"NCT01652469","phase":"PHASE3","title":"Testing of Drugs Erlotinib and Docetaxel in Lung Cancer Patients Classified Regarding Their Outlook Using VeriStrat®.","status":"COMPLETED","sponsor":"ETOP IBCSG Partners Foundation","startDate":"2012-08","conditions":"Carcinoma, Non-Small-Cell Lung","enrollment":81},{"nctId":"NCT03086538","phase":"PHASE2","title":"Pemetrexed Plus Tarceva as Salvage Treatment in EGFR Overexpressed Metastatic Colorectal Cancer Patients Who Were Failed After Standard Chemotherapy","status":"COMPLETED","sponsor":"Samsung Medical Center","startDate":"2017-05-30","conditions":"Colo-rectal Cancer","enrollment":29},{"nctId":"NCT02574078","phase":"PHASE1, PHASE2","title":"A Study of Nivolumab in Advanced Non-Small Cell Lung Cancer (NSCLC)","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2015-11-23","conditions":"Non-Small Cell Lung Cancer","enrollment":341},{"nctId":"NCT03595644","phase":"PHASE2","title":"Maintenance Targeted Therapy With or Without Stereotactic Body Radiation Therapy for Stage IV Non-small Cell Lung Cancer","status":"COMPLETED","sponsor":"Tongji Hospital","startDate":"2017-02-12","conditions":"Stage IV Non-small Cell Lung Cancer","enrollment":74},{"nctId":"NCT02893332","phase":"PHASE3","title":"Stereotactic Body Radiation Therapy (SBRT) in Newly Diagnosed Advanced Staged Lung Adenocarcinoma (Sindas)","status":"TERMINATED","sponsor":"Sichuan Provincial People's Hospital","startDate":"2016-01-15","conditions":"Stage IV EGFR Mutated Non-Small Cell Lung Cancer","enrollment":200},{"nctId":"NCT00130728","phase":"PHASE3","title":"A Study to Evaluate the Efficacy of Bevacizumab in Combination With Tarceva for Advanced Non-Small Cell Lung Cancer","status":"COMPLETED","sponsor":"Genentech, Inc.","startDate":"2005-06-08","conditions":"Non-Small Cell Lung Cancer","enrollment":636},{"nctId":"NCT00547105","phase":"PHASE2","title":"Erlotinib and SBRT in Treating Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer","status":"COMPLETED","sponsor":"University of Texas Southwestern Medical Center","startDate":"2007-06-25","conditions":"Lung Cancer","enrollment":24},{"nctId":"NCT00966472","phase":"PHASE1","title":"Phase I Study of a Statin + Erlotinib for Advanced Solid Malignancies With Focus on Squamous Cell Carcinomas and NSCLC","status":"COMPLETED","sponsor":"Ottawa Hospital Research Institute","startDate":"2009-03","conditions":"Squamous Cell Carcinoma, Non-Small Cell Lung Cancer","enrollment":24},{"nctId":"NCT02117024","phase":"PHASE2","title":"A Phase 2 Study of Viagenpumatucel-L (HS-110) in Patients With Non-Small Cell Lung Cancer","status":"TERMINATED","sponsor":"Heat Biologics","startDate":"2014-07","conditions":"Non Small Cell Lung Cancer","enrollment":66},{"nctId":"NCT00848718","phase":"PHASE1","title":"A Phase I Study of MK-2206 in Combination With Standard Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors (MK-2206-003)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2009-03-17","conditions":"Locally Advanced, Metastatic Solid Tumors","enrollment":77},{"nctId":"NCT02080078","phase":"PHASE1","title":"A Phase I Dose Escalation Study of Erlotinib in Combination With Theophylline","status":"TERMINATED","sponsor":"AHS Cancer Control Alberta","startDate":"2014-09","conditions":"Non-small Cell Lung Cancer, Advanced Solid Malignancies","enrollment":15},{"nctId":"NCT02155465","phase":"PHASE1, PHASE2","title":"Trial of Ruxolitinib and Erlotinib in Patients With EGFR-mutant Lung Adenocarcinoma With Acquired Resistance to Erlotinib","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2014-06","conditions":"Lung Cancer","enrollment":22},{"nctId":"NCT00954512","phase":"PHASE1, PHASE2","title":"Study of Robatumumab (SCH 717454, MK-7454) in Combination With Different Treatment Regimens in Participants With Advanced Solid Tumors (P04722, MK-7454-004)","status":"TERMINATED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2009-09-25","conditions":"Neoplasms","enrollment":15},{"nctId":"NCT01998126","phase":"PHASE1","title":"Combination Checkpoint Inhibitor Plus Erlotinib or Crizotinib for EGFR or ALK Mutated Stage IV Non-small Cell Lung Cancer","status":"COMPLETED","sponsor":"University of Utah","startDate":"2013-12-02","conditions":"Non-small Cell Lung Cancer","enrollment":14},{"nctId":"NCT00998036","phase":"PHASE1","title":"Study of Temsirolimus, Erlotinib and Cisplatin in Solid Tumors","status":"COMPLETED","sponsor":"Columbia University","startDate":"2009-09","conditions":"Triple Negative Breast Cancer","enrollment":9},{"nctId":"NCT00428194","phase":"PHASE1","title":"Erlotinib, Cisplatin, and Radiation Therapy in Treating Patients With Stage IB-Stage IVA Cervical Cancer","status":"WITHDRAWN","sponsor":"Masonic Cancer Center, University of Minnesota","startDate":"2007-01","conditions":"Cervical Cancer","enrollment":""},{"nctId":"NCT01650506","phase":"PHASE1","title":"Study of Erlotinib and Metformin in Triple Negative Breast Cancer","status":"COMPLETED","sponsor":"Columbia University","startDate":"2012-07","conditions":"Breast Cancer","enrollment":8},{"nctId":"NCT01965275","phase":"PHASE2","title":"High-Dose,Pulsatile Erlotinib/Gefitinib for Advanced NSCLC Patients After Failure of Standard Dose EGFR-TKIs","status":"UNKNOWN","sponsor":"Anhui Medical University","startDate":"2013-10","conditions":"Self Efficacy, Drug Toxicity","enrollment":20},{"nctId":"NCT03071705","phase":"NA","title":"Metformin Plus TKI Use in Patients With Non-Small Cell Lung Carcinoma","status":"UNKNOWN","sponsor":"Instituto Nacional de Cancerologia de Mexico","startDate":"2016-03","conditions":"Non-Small Cell Adenocarcinoma, Tyrosine Kinase Mutation, EGFR Gene Mutation","enrollment":120},{"nctId":"NCT01482377","phase":"PHASE1","title":"A Study of RO5479599 Alone or in Combination With Cetuximab or Erlotinib in Participants With Metastatic and/or Locally Advanced Malignant Human Epidermal Growth Factor Receptor (HER3) Expressing Solid Tumors of Epithelial Cell Origin","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2011-12","conditions":"Neoplasms","enrollment":145},{"nctId":"NCT02015728","phase":"NA","title":"Selecting Patient-Specific Biologically Targeted Therapy for Pediatric Patients With Refractory Or Recurrent Brain Tumors","status":"UNKNOWN","sponsor":"Seattle Children's Hospital","startDate":"2013-12","conditions":"Recurrent Childhood Brain Tumor","enrollment":20},{"nctId":"NCT00811993","phase":"PHASE1","title":"A Study of R1507 in Combination With Multiple Standard Chemotherapy Treatments in Patients With Advanced Solid Tumors","status":"TERMINATED","sponsor":"Hoffmann-La Roche","startDate":"2009-02","conditions":"Neoplasms","enrollment":104},{"nctId":"NCT00391586","phase":"PHASE2","title":"Erlotinib and Standard Platinum-Based Chemotherapy for Newly Diagnosed, Advanced Non-Small Cell Carcinoma of the Lung","status":"TERMINATED","sponsor":"New Mexico Cancer Research Alliance","startDate":"2006-07","conditions":"Carcinoma, Non-Small-Cell Lung","enrollment":45},{"nctId":"NCT00652366","phase":"PHASE2","title":"A Dose-Escalation to Rash Study of Tarceva (Erlotinib) Plus Gemcitabine in Patients With Metastatic Pancreatic Cancer","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2008-05","conditions":"Pancreatic Cancer","enrollment":467},{"nctId":"NCT01465815","phase":"PHASE1, PHASE2","title":"Phase I/II Study of Postoperative Adjuvant Chemoradiation for Advanced-Stage Cutaneous Squamous Cell Carcinoma of the Head and Neck (cSCCHN)","status":"WITHDRAWN","sponsor":"OHSU Knight Cancer Institute","startDate":"2011-12","conditions":"Recurrent Skin Cancer, Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity, Squamous Cell Carcinoma of the Skin","enrollment":""},{"nctId":"NCT00049166","phase":"PHASE1","title":"Erlotinib and Radiation Therapy With or Without Cisplatin in Treating Patients With Mouth or Throat Cancer","status":"COMPLETED","sponsor":"National Cancer Institute (NCI)","startDate":"2002-10","conditions":"Stage II Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage II Squamous Cell Carcinoma of the Oropharynx, Stage III Squamous Cell Carcinoma of the Lip and Oral Cavity","enrollment":48},{"nctId":"NCT01728181","phase":"PHASE1, PHASE2","title":"A Phase I/II Study of Tivozanib and Erlotinib as Initial Treatment for Metastatic Non-small Cell Lung Cancer Assigned by VeriStrat® Serum Proteomic Evaluation","status":"WITHDRAWN","sponsor":"University of Utah","startDate":"2013-11","conditions":"Non-small Cell Lung Cancer, Stage IV Disease, EGFR Unknown or Wild-type","enrollment":""},{"nctId":"NCT01600807","phase":"PHASE1, PHASE2","title":"OSI-906 With Gemcitabine and Erlotinib for Metastatic Ductal Adenocarcinoma of the Pancreas","status":"WITHDRAWN","sponsor":"Dana-Farber Cancer Institute","startDate":"","conditions":"Pancreatic Cancer, Metastatic","enrollment":""},{"nctId":"NCT00085839","phase":"PHASE2","title":"Erlotinib vs. Standard Chemotherapy in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) and Eastern Cooperative Oncology Group (ECOG)Performance Status (PS) 2","status":"COMPLETED","sponsor":"OSI Pharmaceuticals","startDate":"2004-02","conditions":"Non-Small Cell Lung Cancer","enrollment":103}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":32,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Tarceva"],"phase":"phase_2","status":"active","brandName":"Erlotinib, standard dose","genericName":"Erlotinib, standard dose","companyName":"Hoffmann-La Roche","companyId":"roche","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Erlotinib is a tyrosine kinase inhibitor that targets the epidermal growth factor receptor (EGFR) tyrosine kinase. Used for Non-small cell lung cancer, Pancreatic cancer.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}